The Drug Discovery Services Companies Quadrant provides an in-depth analysis of the drug discovery services market, highlighting key players, technological advancements, and trends. Conducted by MarketsandMarkets 360 Quadrants, over 150 companies were evaluated, recognizing the Top 25 as leaders in the industry. Contract Research Organizations (CROs) offer extensive services such as hit identification and hit-to-lead optimization. Market growth is fueled by increased R&D investments, a growing drug development pipeline, and the high costs of in-house development. Key players like Labcorp, Evotec, and Selvita focus on innovation and strategic partnerships.\n\nDublin, Aug. 14, 2025 (GLOBE NEWSWIRE) -- The \"Drug Discovery Services - Company Evaluation Report, 2025\" report has been added to ResearchAndMarkets.com's offering. The Drug Discovery Services Companies Quadrant is a comprehensive industry analysis that provides valuable insights into the global market for Drug Discovery Services. This quadrant offers a detailed evaluation of key market players, technological advancements, product innovations, and emerging trends shaping the industry. 360 Quadrants evaluated over 150 companies, of which the Top 25 Drug Discovery Services Companies were categorized and recognized as the quadrant leaders. Contract Research Organizations (CROs) provide a wide range of drug discovery services, including hit identification, medicinal chemistry, and hit-to-lead optimization. The growth of the drug discovery services market is primarily driven by increasing R&D investments from pharmaceutical and biopharmaceutical companies, coupled with the expanding drug development pipeline, which has led to a greater need for outsourced analytical testing.\n\nAdditional growth drivers include rising research initiatives for rare diseases and orphan drugs, as well as the high costs associated with in-house drug development. Furthermore, advancements in technology, the emergence of innovative drug discovery methods, the expiration of key drug patents, and the growing demand for specialized testing services among end users are creating new opportunities for market players. The 360 Quadrant maps the Drug Discovery Services companies based on criteria such as revenue, geographic presence, growth strategies, investments, and sales strategies for the market presence of the Drug Discovery Services quadrant. Prominent players are increasingly focusing on product launches and enhancements, investments, partnerships, collaborations, joint ventures, funding, acquisitions, expansions, agreements, sales contracts, and alliances to strengthen their presence in the global market.\n\nTop 3 Companies\n\nLabCorp: LabCorp is a leading healthcare diagnostics company that delivers a broad range of clinical laboratory services and comprehensive drug development support. It serves a diverse client base, including hospitals, managed care organizations, and pharmaceutical and biotechnology firms. The company operates through two main segments: LabCorp Diagnostics (Dx) and Biopharma Laboratory Services (BLS). The Dx segment functions as an independent clinical laboratory network, encompassing approximately 2,000 patient service centers across the U.S. The BLS segment supports the drug discovery and development pipeline, offering both early-phase and late-phase services. These include lead optimization, in vivo pharmacology, toxicology studies, and disease modeling for pharmaceutical, biopharmaceutical, and medical device companies. LabCorp is also a key provider of laboratory testing for the chemical and agrochemical industries and is recognized as a market leader in toxicology, central laboratory services, and discovery research.\n\nEvotec: Evotec is a globally recognized drug discovery and development partner, collaborating with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capital firms. The company offers a comprehensive suite of drug discovery services through fee-for-service projects, integrated discovery alliances, development partnerships, licensing agreements, and strategic consulting. Evotec operates through two core segments: EVT Execute and EVT Innovate. Both segments contribute to the company's drug discovery offerings. EVT Execute focuses on scalable and high-quality drug discovery services, while EVT Innovate is centered on building and advancing innovative therapeutic projects through strategic partnerships and internal pipeline development.\n\nSelvita: Selvita is a drug discovery company that provides a wide range of research and development services to support pharmaceutical innovation. Its capabilities span medicinal chemistry, process research, preclinical studies, ADME/DMPK, protein chemistry, analytical and industrial chemistry, and bioinformatics. The company also conducts comparative studies for biosimilars and undertakes integrated drug discovery projects, enabling clients to access end-to-end solutions tailored to their drug development needs.\n\nKey Topics Covered: 1 Introduction 1.1 Market Definition 1.2 Stakeholders 2 Executive Summary 3 Market Overview 3.1 Introduction 3.2 Market Dynamics 3.2.1 Drivers 3.2.1.1 Booming Research & Development Expenditure in Pharma-Biotech Sector 3.2.1.2 Growing Pipeline of Pharmaceutical and Biopharmaceutical Companies 3.2.1.3 Rising Research on Rare Diseases and Orphan Drugs 3.2.1.4 Increasing Reliance on Outsourcing due to Costly In-House Drug Development 3.2.2 Restraints 3.2.2.1 Stringent Regulations 3.2.3 Opportunities 3.2.3.1 Technological Advancements and New Drug Discovery Techniques 3.2.3.2 Rising Demand for Specialized Testing Services 3.2.3.3 Patent Expiry of Key Biologics 3.2.3.4 High Growth Prospects in Emerging Markets 3.2.4 Challenges 3.2.4.1 Economic Uncertainties Worldwide 3.2.5 Market Trends 3.2.5.1 Adoption of AI in Drug Discovery 3.2.5.2 Increased Outsourcing in Emerging Economies 3.2.5.3 Consolidation of Contract Research Organizations 3.2.5.4 Integrated End-To-End R&D Service Offerings 3.3 Trends/Disruptions Impacting Customer Business 3.4 Supply Chain Analysis 3.5 Value Chain Analysis 3.6 Ecosystem Analysis 3.7 Technology Analysis 3.7.1 Key Technologies 3.7.1.1 High-Throughput Screening 3.7.1.2 CRISPR Gene Editing 3.7.1.3 Structure-Based Drug Design/Computer-Aided Drug Design 3.7.2 Complementary Technologies 3.7.2.1 Automated Liquid Handling 3.7.2.2 In Silico Modeling 3.7.2.3 Patient-Derived Xenografts and Organoids 3.7.3 Adjacent Technologies 3.7.3.1 Nanotechnology 3.7.3.2 Synthetic Biology 3.7.3.3 Organ-On-A-Chip Technology 3.8 Patent Analysis 3.9 Key Conferences and Events, 2025-2026 3.10 Porter's Five Forces Analysis 3.10.1 Bargaining Power of Suppliers 3.10.2 Bargaining Power of Buyers 3.10.3 Threat of New Entrants 3.10.4 Threat of Substitutes 3.10.5 Intensity of Competitive Rivalry 3.11 Impact of AI on Drug Discovery Services Market 3.11.1 Introduction 3.11.2 Market Potential of AI in Drug Discovery Services 3.11.3 AI Use Cases 3.11.4 Future of Generative AI in Drug Discovery Services Market 4 Competitive Landscape 4.1 Introduction 4.2 Key Player Strategies/Right to Win 4.2.1 Overview of Strategies Adopted by Key Players in Drug Discovery Services Market 4.3 Revenue Analysis, 2020-2024 4.4 Market Share Analysis, 2024 4.5 Company Valuation and Financial Metrics 4.6 Brand/Service Comparison 4.6.1 Thermo Fisher Scientific Inc. (US) 4.6.2 Charles River Laboratories (US) 4.6.3 Labcorp (US) 4.6.4 Wuxi Apptec (China) 4.6.5 Pharmaron (China) 4.7 Company Evaluation Matrix: Key Players, 2024 4.7.1 Stars 4.7.2 Emerging Leaders 4.7.3 Pervasive Players 4.7.4 Participants 4.7.5 Company Footprint: Key Players, 2024 4.7.5.1 Company Footprint 4.7.5.2 Region Footprint 4.7.5.3 Process Footprint 4.7.5.4 Type Footprint 4.7.5.5 Therapeutic Area Footprint 4.7.5.6 Drug Type Footprint 4.8 Company Evaluation Matrix: Startups/SMEs, 2024 4.8.1 Progressive Companies 4.8.2 Responsive Companies 4.8.3 Dynamic Companies 4.8.4 Starting Blocks 4.8.5 Competitive Benchmarking: Startups/SMEs 4.8.5.1 Detailed List of Key Startups/SMEs 4.8.5.2 Competitive Benchmarking of Key Startups/SMEs 4.9 Competitive Scenario 4.9.1 Service Launches 4.9.2 Deals 4.9.3 Expansions 4.9.4 Other Developments 5 Company Profiles\n\nThermo Fisher Scientific Inc.\nCharles River Laboratories\nWuxi Apptec\nPharmaron\nLabcorp\nEvotec\nSyngene International Limited\nEurofins Scientific\nJubilant Pharmova Limited\nGenscript\nFrontage Holdings Corporation\nPiramal Enterprises Ltd.\nAurigene Pharmaceutical Services Ltd.\nCuria Global, Inc.\nShanghai Medicilon Inc.\nSygnature Discovery\nSelvita\nViva Biotech\nTcg Lifesciences Pvt. Ltd.\nShanghai Chempartner\nDomainex\nNuvisan GmbH\nDalton Pharma Services\nAragen Life Sciences Ltd.\nOncodesign Services\n\nFor more information about this report visit https://www.researchandmarkets.com/r/k2bd6i\n\nAbout ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Drug Discovery Services Company Evaluation Report 2025 | LabCorp, Evotec, and Selvita Lead with Comprehensive Research and Laboratory Services

The Drug Discovery Services Company Evaluation Report 2025, published by MarketsandMarkets 360 Quadrants, analyzes the global drug discovery services market, evaluating over 150 companies and identifying the Top 25 leaders. The report highlights key players such as LabCorp, Evotec, and Selvita, emphasizing their roles in providing services like hit identification, medicinal chemistry, and hit-to-lead optimization. Market growth is driven by rising R&D investments, an expanding drug development pipeline, increased outsourcing due to high in-house development costs, and advancements in technologies such as AI, CRISPR, and organ-on-a-chip. The report also covers market dynamics, competitive strategies, financial metrics, and regional footprints of major companies, including Thermo Fisher Scientific, Charles River Laboratories, Wuxi Apptec, and others.